Profiling of ribose methylations in ribosomal RNA from diffuse large B-cell lymphoma patients for evaluation of ribosomes as drug targets

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Profiling of ribose methylations in ribosomal RNA from diffuse large B-cell lymphoma patients for evaluation of ribosomes as drug targets. / Krogh, Nicolai; Asmar, Fazila; Côme, Christophe Roger Michel; Fibiger Munch-Petersen, Helga; Grønbæk, Kirsten; Nielsen, Henrik.

I: NAR Cancer, Bind 2, Nr. 4, zcaa035, 04.12.2020.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Krogh, N, Asmar, F, Côme, CRM, Fibiger Munch-Petersen, H, Grønbæk, K & Nielsen, H 2020, 'Profiling of ribose methylations in ribosomal RNA from diffuse large B-cell lymphoma patients for evaluation of ribosomes as drug targets', NAR Cancer, bind 2, nr. 4, zcaa035. https://doi.org/10.1093/narcan/zcaa035

APA

Krogh, N., Asmar, F., Côme, C. R. M., Fibiger Munch-Petersen, H., Grønbæk, K., & Nielsen, H. (2020). Profiling of ribose methylations in ribosomal RNA from diffuse large B-cell lymphoma patients for evaluation of ribosomes as drug targets. NAR Cancer, 2(4), [zcaa035]. https://doi.org/10.1093/narcan/zcaa035

Vancouver

Krogh N, Asmar F, Côme CRM, Fibiger Munch-Petersen H, Grønbæk K, Nielsen H. Profiling of ribose methylations in ribosomal RNA from diffuse large B-cell lymphoma patients for evaluation of ribosomes as drug targets. NAR Cancer. 2020 dec. 4;2(4). zcaa035. https://doi.org/10.1093/narcan/zcaa035

Author

Krogh, Nicolai ; Asmar, Fazila ; Côme, Christophe Roger Michel ; Fibiger Munch-Petersen, Helga ; Grønbæk, Kirsten ; Nielsen, Henrik. / Profiling of ribose methylations in ribosomal RNA from diffuse large B-cell lymphoma patients for evaluation of ribosomes as drug targets. I: NAR Cancer. 2020 ; Bind 2, Nr. 4.

Bibtex

@article{57f08df387cd4a23801e8daf4c748930,
title = "Profiling of ribose methylations in ribosomal RNA from diffuse large B-cell lymphoma patients for evaluation of ribosomes as drug targets",
abstract = "Cancer cells are addicted to ribosome biogenesis and high levels of translation. Thus, differential inhibition of cancer cells can be achieved by targeting aspects of ribosome biogenesis or ribosome function. Using RiboMeth-seq for profiling of the ∼112 2′-O-Me sites in human ribosomal RNA, we demonstrated pronounced hypomethylation at several sites in patient-derived diffuse large B-cell lymphoma (DLBCL) cell lines with a more severe perturbation in ABC-DLBCL compared to GBC-DLBCL. We extended our analysis to tumor samples from patients and demonstrated significant changes to the ribosomal modification pattern that appeared to consist of cell growth-related as well as tumor-specific changes. Sites of hypomethylation in patient samples are discussed as potential drug targets, using as an example a site in the small subunit (SSU-C1440) located in a ribosomal substructure that can be linked to DLBCL pathogenesis.",
author = "Nicolai Krogh and Fazila Asmar and C{\^o}me, {Christophe Roger Michel} and {Fibiger Munch-Petersen}, Helga and Kirsten Gr{\o}nb{\ae}k and Henrik Nielsen",
year = "2020",
month = dec,
day = "4",
doi = "10.1093/narcan/zcaa035",
language = "English",
volume = "2",
journal = "NAR Cancer",
issn = "2632-8674",
publisher = "Oxford University Press",
number = "4",

}

RIS

TY - JOUR

T1 - Profiling of ribose methylations in ribosomal RNA from diffuse large B-cell lymphoma patients for evaluation of ribosomes as drug targets

AU - Krogh, Nicolai

AU - Asmar, Fazila

AU - Côme, Christophe Roger Michel

AU - Fibiger Munch-Petersen, Helga

AU - Grønbæk, Kirsten

AU - Nielsen, Henrik

PY - 2020/12/4

Y1 - 2020/12/4

N2 - Cancer cells are addicted to ribosome biogenesis and high levels of translation. Thus, differential inhibition of cancer cells can be achieved by targeting aspects of ribosome biogenesis or ribosome function. Using RiboMeth-seq for profiling of the ∼112 2′-O-Me sites in human ribosomal RNA, we demonstrated pronounced hypomethylation at several sites in patient-derived diffuse large B-cell lymphoma (DLBCL) cell lines with a more severe perturbation in ABC-DLBCL compared to GBC-DLBCL. We extended our analysis to tumor samples from patients and demonstrated significant changes to the ribosomal modification pattern that appeared to consist of cell growth-related as well as tumor-specific changes. Sites of hypomethylation in patient samples are discussed as potential drug targets, using as an example a site in the small subunit (SSU-C1440) located in a ribosomal substructure that can be linked to DLBCL pathogenesis.

AB - Cancer cells are addicted to ribosome biogenesis and high levels of translation. Thus, differential inhibition of cancer cells can be achieved by targeting aspects of ribosome biogenesis or ribosome function. Using RiboMeth-seq for profiling of the ∼112 2′-O-Me sites in human ribosomal RNA, we demonstrated pronounced hypomethylation at several sites in patient-derived diffuse large B-cell lymphoma (DLBCL) cell lines with a more severe perturbation in ABC-DLBCL compared to GBC-DLBCL. We extended our analysis to tumor samples from patients and demonstrated significant changes to the ribosomal modification pattern that appeared to consist of cell growth-related as well as tumor-specific changes. Sites of hypomethylation in patient samples are discussed as potential drug targets, using as an example a site in the small subunit (SSU-C1440) located in a ribosomal substructure that can be linked to DLBCL pathogenesis.

U2 - 10.1093/narcan/zcaa035

DO - 10.1093/narcan/zcaa035

M3 - Journal article

C2 - 34316692

VL - 2

JO - NAR Cancer

JF - NAR Cancer

SN - 2632-8674

IS - 4

M1 - zcaa035

ER -

ID: 257604703